1. Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and SU cohort with no baseline CVD (panel C); saxagliptin and sitagliptin cohorts with no baseline CVD (panel D). *HR treating SUs as reference (HR < 1 indicates a lower rate for DPP-4i) (95% CI 0.778–1.151), P = †HR treating sitagliptin as reference (HR < 1 indicates a lower rate for saxagliptin) (95% CI 0.699–1.278), P = ‡HR treating SUs as reference (HR < 1 indicates a lower rate for DPP-4i) (95% CI 0.384–0.892), P = §HR treating sitagliptin as reference (HR < 1 indicates a lower rate for saxagliptin) (95% CI 0.560–1.749), P =
Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and SU cohort with no baseline CVD (panel C); saxagliptin and sitagliptin cohorts with no baseline CVD (panel D). *HR treating SUs as reference (HR < 1 indicates a lower rate for DPP-4i) (95% CI 0.778–1.151), P = †HR treating sitagliptin as reference (HR < 1 indicates a lower rate for saxagliptin) (95% CI 0.699–1.278), P = ‡HR treating SUs as reference (HR < 1 indicates a lower rate for DPP-4i) (95% CI 0.384–0.892), P = §HR treating sitagliptin as reference (HR < 1 indicates a lower rate for saxagliptin) (95% CI 0.560–1.749), P = Dotted lines around the survival curve point estimates represent 95% confidence bands.
Alex Z. Fu et al. Dia Care 2016;39:
©2016 by American Diabetes Association